MedPath

Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

Phase 2
Active, not recruiting
Conditions
Spinal Cord Injury (SCI)
Interventions
Drug: Placebo
Registration Number
NCT04295538
Lead Sponsor
AbbVie
Brief Summary

Acute Spinal Cord Injury (SCI) is a rare injury that leads to permanent neuromotor impairment and sudden disability. Approximately 25,000 people experience cervical SCI in the United States, Europe, and Japan every year. The purpose of this study is to see if elezanumab is safe and assess change in Upper Extremity Motor Score (UEMS) in participants with acute traumatic cervical SCI.

Elezanumab is an investigational drug being developed for the treatment of SCI. Elezanumab is a monoclonal antibody, that binds to an inhibitor of neuronal regeneration and neutralizes the inhibitor, thus potentially promoting neuroregeneration. This study is "double-blinded", which means that neither trial participants nor the study doctors will know who will be given which study drug. Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will be assigned to placebo. Participants 18-75 years of age with a SCI will be enrolled. Approximately 54 participants will be enrolled in the study in approximately 49 sites worldwide.

Participants will receive intravenous (IV) doses of elezanumab or placebo within 24 hours of injury and every 4 weeks thereafter through Week 48 for a total of 13 doses.

There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Acute traumatic cervical spinal cord injury (SCI), neurological level of injury of C4, C5, C6, or C7 with no damage to cord in thoracic (T2 and beyond) and lumbar regions that, in the investigator's opinion, would significantly limit recovery.
  • Maximum screening UEMS of 32.
  • American Spinal Injury Association Impairment Scale (AIS) grade A or B at Screening.
  • Able to initiate study drug administration within 24 hours of injury.
  • Participants with comorbid conditions that, in the investigator's opinion, are clinically stable and not expected to meaningfully progress in the following 12 months, may be considered eligible to participate.
Exclusion Criteria
  • Evidence of complete spinal cord transection.
  • Significant concomitant head injury with a clinically significant abnormality on a head computed tomography (CT).
  • One or more upper extremity muscle groups untestable (e.g., immobilized or restricted by a cast) during the screening International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) examination.
  • Known receipt of any other investigational product within 30 days or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study.
  • Female who is pregnant, breastfeeding, or considering becoming pregnant during the study or for within 39 weeks (5 half-lives) after the last dose of study drug.
  • The cause of the acute SCI is one of the following: from gunshot or penetrating/stab wound; non-traumatic SCI, results of seizure, or known attempted suicide.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboParticipants will receive placebo for elezanumab
ElezanumabElezanumabParticipants will receive elezanumab dose A
Primary Outcome Measures
NameTimeMethod
Upper Extremity Motor Score (UEMS)52 Weeks

The UEMS is a subscore of the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) that grades function of 5 key muscles in the upper limbs on a scale of 0 to 5 on each side from total paralysis to active full range of movement, respectively.

Secondary Outcome Measures
NameTimeMethod
Change from Baseline in Spinal Cord Independence Measures (SCIM III) Self-Care ScoreWeek 0 through Week 52

The SCIM III self-care score addresses four areas of self-care management: feeding, grooming, bathing, and dressing. It has a total of 4 questions. Scores range from 0-20 where a score of 0 defines total dependence and 20 is indicative of complete independence.

Change in Upper Extremity Motor Score (UEMS) From BaselineWeek 0 through Week 52

The UEMS is a subscore of the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) that grades function of 5 key muscles in the upper limbs on a scale of 0 to 5 on each side from total paralysis to active full range of movement, respectively.

Trial Locations

Locations (41)

Thomas Jefferson University Hospital /ID# 215460

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

National Hospital Organization Murayama Medical Center /ID# 223492

๐Ÿ‡ฏ๐Ÿ‡ต

Musashimurayama-shi, Tokyo, Japan

Japan Organization of Occupational Health and Safety Spinal Injuries Centre /ID# 224141

๐Ÿ‡ฏ๐Ÿ‡ต

Iizuka-shi, Japan

The Chaim Sheba Medical Center /ID# 240917

๐Ÿ‡ฎ๐Ÿ‡ฑ

Ramat Gan, Tel-Aviv, Israel

Hospital Universitario y Politecnico La Fe /ID# 217797

๐Ÿ‡ช๐Ÿ‡ธ

Valencia, Spain

Duke Cancer Center /ID# 216888

๐Ÿ‡บ๐Ÿ‡ธ

Durham, North Carolina, United States

Oregon Medical Research Center /ID# 227371

๐Ÿ‡บ๐Ÿ‡ธ

Portland, Oregon, United States

Hospital Universitario 12 de Octubre /ID# 225354

๐Ÿ‡ช๐Ÿ‡ธ

Madrid, Spain

Shepherd Center, Inc /ID# 230370

๐Ÿ‡บ๐Ÿ‡ธ

Atlanta, Georgia, United States

Northwestern University Feinberg School of Medicine /ID# 218009

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Tufts Medical Center /ID# 225410

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Boston University School of Medicine /ID# 218371

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Brigham & Women's Hospital /ID# 216342

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center /ID# 218149

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Washington University-School of Medicine /ID# 215325

๐Ÿ‡บ๐Ÿ‡ธ

Saint Louis, Missouri, United States

Hackensack Univ Med Ctr /ID# 215754

๐Ÿ‡บ๐Ÿ‡ธ

Hackensack, New Jersey, United States

Rutgers New Jersey School of Medicine /ID# 216212

๐Ÿ‡บ๐Ÿ‡ธ

Newark, New Jersey, United States

Jersey Shore University Medical Center /ID# 218162

๐Ÿ‡บ๐Ÿ‡ธ

Neptune, New Jersey, United States

University of Pennsylvania /ID# 218662

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

University of Virginia Health /ID# 218117

๐Ÿ‡บ๐Ÿ‡ธ

Charlottesville, Virginia, United States

Sentara Norfolk General Hospital /ID# 218302

๐Ÿ‡บ๐Ÿ‡ธ

Norfolk, Virginia, United States

West Virginia University Hospitals /ID# 217344

๐Ÿ‡บ๐Ÿ‡ธ

Morgantown, West Virginia, United States

Royal Adelaide Hospital /ID# 216953

๐Ÿ‡ฆ๐Ÿ‡บ

Adelaide, South Australia, Australia

QEII - Health Sciences Centre /ID# 215249

๐Ÿ‡จ๐Ÿ‡ฆ

Halifax, Nova Scotia, Canada

Toronto Western Hospital /ID# 215214

๐Ÿ‡จ๐Ÿ‡ฆ

Toronto, Ontario, Canada

The Ottawa Hospital Civic Campus /ID# 215270

๐Ÿ‡จ๐Ÿ‡ฆ

Ottawa, Ontario, Canada

Foothills Medical Centre /ID# 214790

๐Ÿ‡จ๐Ÿ‡ฆ

Calgary, Alberta, Canada

Funabashi Municipal Medical Center /ID# 225599

๐Ÿ‡ฏ๐Ÿ‡ต

Funabashi-shi, Chiba, Japan

NHO Nagoya Medical Center /ID# 239617

๐Ÿ‡ฏ๐Ÿ‡ต

Nagoya-shi, Aichi, Japan

CIUSSS du Nord-de-l'ile-de-Montrรฉal_Hopital du Sacrรฉ-Coeur de Montrรฉal /ID# 215210

๐Ÿ‡จ๐Ÿ‡ฆ

Montreal, Quebec, Canada

Duplicate_Inha University Hospital /ID# 238890

๐Ÿ‡ฐ๐Ÿ‡ท

์ค‘๊ตฌ, Incheon Gwang Yeogsi, Korea, Republic of

Complejo Hospitalario Universitario A Coruรฑa /ID# 216384

๐Ÿ‡ช๐Ÿ‡ธ

A Coruรฑa, A Coruna, Spain

Ajou University Hospital /ID# 241119

๐Ÿ‡ฐ๐Ÿ‡ท

Suwon-si, Gyeonggido, Korea, Republic of

Hospital Universitario Virgen del Rocio /ID# 225692

๐Ÿ‡ช๐Ÿ‡ธ

Sevilla, Spain

Hospital Universitario Vall d'Hebron /ID# 217794

๐Ÿ‡ช๐Ÿ‡ธ

Barcelona, Spain

Hospital Nacional de Paraplejicos /ID# 225508

๐Ÿ‡ช๐Ÿ‡ธ

Toledo, Spain

University of California Davis Health /ID# 224892

๐Ÿ‡บ๐Ÿ‡ธ

Sacramento, California, United States

University of Louisville Hospital /ID# 215948

๐Ÿ‡บ๐Ÿ‡ธ

Louisville, Kentucky, United States

Regents of the University of Michigan /ID# 215890

๐Ÿ‡บ๐Ÿ‡ธ

Ann Arbor, Michigan, United States

Virginia Commonwealth University Medical Center Main Hospital /ID# 217481

๐Ÿ‡บ๐Ÿ‡ธ

Richmond, Virginia, United States

Wisconsin Medical Center /ID# 215610

๐Ÿ‡บ๐Ÿ‡ธ

Milwaukee, Wisconsin, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath